


# Pieris Pharmaceuticals (Fri, May 03, 2024)

Buy candidate since Apr 24, 2024

Loss -7.12%

StockInvest.us  
Gyneju st. 14, "ROCKIT"  
Vilnius, LT-01109  
Lithuania



score: **-0.429**  
#10143/ 30045

Trend:	Buy
MV Long:	Buy
MV Short:	Sell
Pivot:	Sell
Volume:	Sell
MACD:	Buy

## Tech commentaries:

The **Pieris Pharmaceuticals** stock price fell by **-1.42%** on the last day (Friday, 3rd May 2024) from **\$11.24** to **\$11.08**. It has now fallen 3 days in a row. During the last trading day the stock fluctuated **5.66%** from a day low at **\$10.60** to a day high of **\$11.20**. The price has fallen in 6 of the last 10 days but is still up by **7541.38%** over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by **-50 thousand** shares and in total, **31** thousand shares were bought and sold for approximately **\$345.80** thousand.

The stock lies in the upper part of a very wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at **\$13.07** will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise **172.62%** during the next 3 months and, with a 90% probability hold a price between **\$3.67** and **\$35.63** at the end of this 3-month period.

The **Pieris Pharmaceuticals** stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately **\$11.53**. On a fall, the stock will find some support from the long-term average at approximately **\$3.12**. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on **Tuesday, April 23, 2024**, and so far it has fallen -7.67%. Further fall is indicated until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$11.24**, **\$11.68** and **\$12.00**.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved **\$0.600** between high and low, or **5.66%**. For the last week the stock has had daily average volatility of **4.62%**.

**Pieris Pharmaceuticals** holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

**Risk: Very High**

**Evaluation: Hold/Accumulate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.